The study investigates the efficacy of sorafenib maintenance therapy in patients with FLT3-ITD positive acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Given the prevalence of FLT3-ITD mutations in AML and the associated poor prognosis, successful outcomes from this study could enhance the therapeutic positioning of sorafenib in the AML treatment landscape. The results may influence treatment guidelines and could lead to increased market share for sorafenib, particularly in the context of maintenance therapies. Additionally, the collaboration with multiple prestigious hospitals enhances credibility and may facilitate broader acceptance and adoption of findings within clinical practice. The competitive landscape includes other FLT3 inhibitors, and the study's findings could provide a comparative advantage for sorafenib if superior outcomes are demonstrated.